talipexole has been researched along with Parkinson Disease, Secondary in 5 studies
talipexole: dopamine receptor agonist; structure given in first source
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Talipexole was more potent than pramipexole (10 vs." | 1.30 | Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. ( Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H, 1997) |
| "We examined whether or not the antiparkinsonian activity of talipexole (B-HT 920, 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]-azepine) could be optimised by combination with L-3,4-dihydroxyphenylalanine (L-dopa)." | 1.29 | Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment. ( Fukuda, T; Irifune, M; Nomoto, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Irifune, M | 2 |
| Nomoto, M | 2 |
| Fukuda, T | 2 |
| Domino, EF | 2 |
| Ni, L | 2 |
| Zhang, H | 2 |
| Kohno, Y | 2 |
| Sasa, M | 2 |
| Kondo, T | 1 |
| Shimada, H | 1 |
| Hatori, K | 1 |
| Sugita, Y | 1 |
| Mizuno, Y | 1 |
5 other studies available for talipexole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; A | 1994 |
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Bromocriptine; Callithrix; Dopamine | 1993 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Ben | 1997 |
Talipexole protects dopaminergic neurons from methamphetamine toxicity in C57BL/6N mouse.
Topics: Animals; Azepines; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Dopamine | 1998 |
Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: Animals; Azepines; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Mac | 1998 |